Abstract:Human microbiomes, particularly in the gut, could have a major impact on the efficacy and toxicity of drugs. However, gut microbial metabolism is often neglected in the drug discovery and development process. Medicen, a Paris-based human health innovation cluster, has gathered more than 30 international leading experts from pharma, academia, biotech, clinical research organizations, and regulatory science to develop proposals to facilitate the integration of microbiome science into drug discovery and development. Seven subteams were formed to cover the complementary expertise areas of 1) pharma experience and case studies, 2) in silico microbiome–drug interaction, 3) in vitro microbial stability screening, 4) gut fermentation models, 5) animal models, 6) microbiome integration in clinical and regulatory aspects, and 7) microbiome ecosystems and models. Each expert team produced a state-of-the-art report of their respective field highlighting existing microbiome-related tools at every stage of drug discovery and development. The most critical limitations are the growing, but still limited, drug–microbiome interaction data to produce predictive models and the lack of agreed-upon standards despite recent progress. In this paper we will report on and share proposals covering 1) how microbiome tools can support moving a compound from drug discovery to clinical proof-of-concept studies and alert early on potential undesired properties stemming from microbiome-induced drug metabolism and 2) how microbiome data can be generated and integrated in pharmacokinetic models that are predictive of the human situation. Examples of drugs metabolized by the microbiome will be discussed in detail to support recommendations from the working group. SIGNIFICANCE STATEMENT Gut microbial metabolism is often neglected in the drug discovery and development process despite growing evidence of drugs' efficacy and safety impacted by their interaction with the microbiome. This paper will detail existing microbiome-related tools covering every stage of drug discovery and development, current progress, and limitations, as well as recommendations to integrate them into the drug discovery and development process.

Pharma[e]cology: How the Gut Microbiome Contributes to Variations in Drug Response

Drug-microbiota interactions: an emerging priority for precision medicine

The Interplay between Gut Microbiota and Oral Medications and Its Impact on Advancing Precision Medicine

Mapping human microbiome drug metabolism by gut bacteria and their genes

Human Gut Microbiota and Drug Metabolism

Interplays between drugs and the gut microbiome

Interaction between drugs and the gut microbiome

Drug and gut microbe relationships: Moving beyond antibiotics

Integrating the gut microbiome and pharmacology

Exploring Drug Metabolism by the Gut Microbiota: Modes of Metabolism and Experimental Approaches

Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism

Impact of commonly used drugs on the composition and metabolic function of the gut microbiota

Mechanisms and Clinical Implications of Human Gut Microbiota-Drug Interactions in the Precision Medicine Era

Gut microbiome and inflammation in cardiovascular drug response: trends in therapeutic success and commercial focus

Small molecules in the big picture of gut microbiome-host cross-talk

The Influence of Gut Microbiota on Drug Metabolism and Toxicity.

A critical need for 'gut neutrality': mitigating adverse drug–microbiome interactions

Mechanisms of Gastrointestinal Microflora on Drug Metabolism in Clinical Practice.

Gut microbiota-drug interactions in cancer pharmacotherapies: implications for efficacy and adverse effects

Connecting the Dots: Targeting the Microbiome in Drug Toxicity

Gut Microbiome Integration in Drug Discovery and Development of Small Molecules